Organon Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Organon Bundle
Business Model Canvas: Strategic blueprint to drive value, capture market share, boost growth
Unlock the full strategic blueprint behind Organon’s business model: this in-depth Business Model Canvas reveals how the company drives value, captures market share, and maintains competitive advantage. Ideal for entrepreneurs, consultants, and investors seeking actionable insights. The downloadable Word and Excel files provide a section-by-section breakdown for benchmarking and strategy. Purchase now to accelerate your analysis and planning.
Partnerships
CROs and academic research partners
Partnering with CROs and academic research centers accelerates cost‑efficient clinical development across women’s health and biosimilars, leveraging scalable trial operations and expertise while the FDA had approved about 40 biosimilars by 2024. These partners provide access to specialized trial sites and curated patient cohorts, tapping into registries and ClinicalTrials.gov which lists over 460,000 studies. They complement internal R&D with cutting‑edge science and generate peer‑reviewed outcomes that strengthen credibility.
CDMOs and API suppliers
Partnering with CDMOs and API suppliers supports scalable, quality‑assured manufacturing of complex biologics and small molecules while lowering Organon’s capex and preserving flexible capacity. The global CDMO market grew at about an 8% CAGR to 2024, underscoring industry capacity expansion and rapid tech‑transfer capabilities for new launches. These partners ensure GMP compliance and cross‑region supply continuity, reducing launch and lifecycle risks.
Distributors, wholesalers, and pharmacy networks
Distributors, wholesalers and pharmacy networks extend Organons reach across 140+ markets and partner with the three major US wholesalers that supply over 90% of hospitals, enabling last‑mile delivery to hospitals and retail pharmacies. They raise service levels and inventory turns, bolster cold‑chain integrity to limit spoilage, feed demand intelligence on prescribing and seasonal patterns, and support access programs in emerging markets.
Payers, PBMs, and government health systems
Organon negotiates formulary access, reimbursement and tender awards with payers, PBMs and government health systems to secure market entry and multi‑year volume stability; global pharmaceutical sales reached $1.6 trillion in 2024 (IQVIA). It aligns on value evidence, real‑world outcomes and budget impact to drive coverage decisions. Co‑creates affordability schemes for women’s health to expand access.
- Negotiate formulary, reimbursement, tenders
- Align on RWE and budget impact
- Co‑create affordability schemes for women’s health
- Stabilize volume via multi‑year agreements
Patient advocacy and NGO organizations
Patient advocacy and NGO partners inform unmet needs and shape patient‑centric solutions, improving education, adherence and screening in women’s health; WHO notes about 90% of cervical cancer deaths occur in low‑ and middle‑income countries, highlighting screening gaps where joint access initiatives are critical. Partnerships build trust and social impact credentials globally while expanding reach in low‑resource settings.
- Inform unmet needs
- Boost education & adherence
- Scale screening in low‑resource areas
- Strengthen trust & social impact
Leverage 460,000 trials, 8% CDMO CAGR to scale to 140+ markets
Partner with CROs/academia to cut clinical timelines and leverage about 460,000 ClinicalTrials.gov studies; FDA approved ~40 biosimilars by 2024. CDMO/API partnerships support scalable GMP manufacturing amid an ~8% CDMO market CAGR to 2024. Payers, distributors and NGOs secure access across 140+ markets and target LMIC screening gaps where ~90% of cervical cancer deaths occur.
| Partner | Key stat |
|---|---|
| CROs/academia | ~460,000 trials |
| CDMO/API | ~8% CAGR to 2024 |
| Payers/distributors | 140+ markets |
| NGOs | ~90% cervical deaths in LMICs |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas tailored to Organon’s strategy, organized into the 9 classic BMC blocks with full narrative, insights, and competitive advantage analysis. Ideal for presentations, investor or bank discussions, it includes SWOT-linked evaluations and supports validation of product and market decisions using real company data in a clean, polished format.
Customizable Excel Spreadsheet
High-level view of Organon's business model with editable cells, relieving the pain of manual structure by saving hours on formatting while enabling quick team collaboration, board-ready summaries, and fast comparison across models.
Activities
Therapeutic R&D and clinical development
Advance pipelines across contraception, fertility, menopause and related conditions through discovery and IND-enabling work, running Phase I–IV trials and observational studies across global sites. In 2024 Organon continued to prioritize R&D investment to support differentiated clinical and health-economic evidence generation and payer dossiers. All studies adhere to rigorous ethics and regulatory compliance and GCP standards.
Regulatory, quality, and pharmacovigilance
Secure approvals, manage variations, and maintain licenses across 140+ countries (Organon global footprint, 2024) while balancing regional regulatory requirements. Operate a robust QMS and cGMP batch-release processes to ensure product quality and continuity. Continuously monitor safety signals, execute risk-management plans, and maintain inspection readiness across sites and partners.
Manufacturing and supply chain orchestration
Plan, produce, and distribute biologics and small molecules at scale, balancing internal and external CDMOs to hit throughput targets and revenue goals. Optimize cost, yield, and reliability across sites, targeting >95% OEE and continuous margin improvements. Manage cold chain, serialization, and inventory—global cold chain market ~220 billion USD in 2024—while executing business continuity and dual sourcing to mitigate supply disruptions.
Market access and medical affairs engagement
Develop comprehensive value dossiers, HEOR and pricing models to secure reimbursement and formulary placement; RWE/HEOR influenced ~75% of payer decisions in 2024. Educate HCPs with clinical and real‑world evidence to drive guideline inclusion and KOL advocacy. Deploy patient support programs to improve adherence 10–30% and reduce total care costs 5–15% (2024 meta‑analyses).
- Value dossiers: HEOR-driven pricing
- HCP education: RWD + clinical evidence
- Guideline/KOL: inclusion advocacy
- Patient programs: adherence 10–30% gain
Portfolio and lifecycle management
Portfolio and lifecycle management focuses on extending assets via new indications, formulations, and geographies while defending brands after loss of exclusivity through differentiation and reliable supply; it emphasizes prioritizing high‑need women’s health segments and rebalancing the mix between established brands and biosimilars.
- Extend assets: indications, formulations, geographies
- Defend post‑LOE: differentiation, supply reliability
- Prioritize women’s health highest unmet need
- Rebalance portfolio: legacy brands vs biosimilars
Advancing contraception, fertility & menopause: global approvals, CDMO scale and HEOR-driven access
Advance pipelines in contraception, fertility and menopause via discovery, IND enabling and Phase I–IV trials; Organon prioritized R&D in 2024 to support differentiated clinical and HEOR evidence. Maintain approvals across 140+ countries, cGMP/QMS and safety monitoring. Scale production with CDMOs targeting >95% OEE and dual sourcing. Use HEOR/RWE (~75% payer influence in 2024) and patient programs to drive reimbursement and adherence gains.
Full Document Unlocks After Purchase
Business Model Canvas
The document you're previewing is the actual Organon Business Model Canvas—not a mockup or sample—and shows the same content and layout you’ll receive after purchase. When you complete your order, you’ll instantly download this exact file, fully formatted and ready to edit and present. No surprises, just the real deliverable in its complete form.
Resources
Therapeutic IP and regulatory assets
Organon protects key franchises with patents (20-year term from filing), trademarks (renewable every 10 years) and regulatory data exclusivities such as 5 years for US new chemical entities, 7 years for orphan drugs and 6 months pediatric exclusivity. Dossiers and approvals follow ICH CTD standards for global registrations, supported by freedom-to-operate analyses and active legal defenses. Value is maintained via patent term extensions, supplementary protection certificates and strategic labeling updates to broaden indications.
Manufacturing network and tech platforms
Organon leverages biologics capabilities for biosimilars and sterile/specialty lines backed by process know‑how, analytics and QC labs, supported by digital MES, serialization and supply planning tools; a qualified CDMO ecosystem and tech transfer playbooks accelerate scale-up. The global CDMO market reached about US$140 billion in 2024, enabling flexible capacity and reduced capex risk.
Clinical, HEOR, and real‑world data
Clinical trial results, registries and post‑marketing studies generate robust evidence for Organon’s products, with industry post‑marketing commitments rising about 15% in 2024 to support labeling and market access. Health‑economic models and HEOR dossiers quantify value for payers, underpinning pricing and reimbursement decisions across markets. Safety databases enable proactive risk management and inform indication refinement and adherence programs through real‑world insights.
Brand equity and global commercial footprint
Organon is a trusted women’s health leader with established brands and strong HCP, payer and tender relationships, operating in 140+ countries as of 2024.
Multi-channel field forces, broad distributor networks and localized marketing and medical teams sustain market access and product uptake worldwide.
- 140+ countries
- global field forces and distributor networks
- localized marketing & medical capabilities
- trusted women’s health brands
Specialized talent and partnerships
Organon's key resources combine scientists, clinicians, regulatory and market-access experts with supply chain leaders and quality professionals to ensure compliant, scalable delivery of women's health medicines; data science and digital health teams drive evidence generation and patient engagement; strategic alliances span discovery, clinical development, manufacturing and distribution to accelerate time-to-market.
- Scientists, clinicians, regulatory, market access
- Supply chain & quality leaders
- Data science & digital health teams
- Strategic alliances: research to distribution
Regulatory exclusivities, 140+ countries, US$140B CDMO opportunity
Organon’s key resources include patented franchises, regulatory exclusivities (US NCE 5y, orphan 7y, pediatric +6m) and global approvals across 140+ countries. Biologics, sterile manufacturing and CDMO partnerships tap into the ~US$140B CDMO market (2024). Clinical evidence, HEOR and safety databases support pricing and access; cross‑functional teams and digital platforms enable scale‑up and commercialization.
| Metric | 2024 |
|---|---|
| Countries | 140+ |
| CDMO market | US$140B |
| Post‑mkt commitments↑ | ~15% |
Value Propositions
Dedicated focus on women’s health
Dedicated focus on women’s health addresses lifelong needs from contraception to menopause, combining medicines, education and support; Organon, spun off as an independent public company (NYSE: OGN) in 2021, leverages concentrated expertise to drive innovations and signal commitment to underserved conditions affecting roughly 49.6% of the global population.
Access and affordability via biosimilars
Provide high-quality, lower-cost alternatives to biologics, with the global biosimilars market exceeding $15 billion in 2024 and price reductions commonly 20–40% versus originators. Expand treatment reach through payer agreements and tenders, where biosimilar penetration in EU RA and oncology classes often surpasses 50% in leading markets. Maintain rigorous comparability, pharmacovigilance and traceability to ensure safety and deliver sustainable healthcare budget relief estimated in the tens of billions globally.
Reliable global supply of established brands
Assures continuity for critical therapies used worldwide by supplying established brands across over 140 countries as of 2024, ensuring hospitals have familiar, guideline-aligned options. Manages multi‑source manufacturing and risk mitigation through diversified supplier networks and regional inventory buffering to reduce disruptions. Reduces stock‑outs and supports hospital protocols, building trust with providers and payers via consistent delivery and brand reliability.
Evidence‑backed outcomes and safety
Strong clinical trials and real‑world evidence underpin Organon value, and in 2024 regulators increasingly cited RWE in coverage decisions. Robust pharmacovigilance systems boost patient and payer confidence. Clear labeling and targeted education drive appropriate use, enabling reimbursement pathways and guideline inclusion.
- Evidence: regulators cite RWE (2024)
- Safety: enhanced PV → higher confidence
- Use: labeling + education → appropriate prescribing
- Access: supports reimbursement and guideline uptake
Patient support and education programs
Patient support and education programs improve adherence, persistence, and quality of life by providing counseling, automated reminders, and affordability options that lower treatment barriers. By addressing stigma and knowledge gaps in women’s health they enhance clinical outcomes and reduce total cost of care; nonadherence costs US$100–300 billion annually in the US (CDC) and support programs can raise adherence roughly 10–20%.
- Improve adherence: +10–20%
- Reduce costs: US$100–300B nonadherence burden
- Services: counseling, reminders, affordability
- Target: stigma and knowledge gaps in women’s health
Women's health medicines and biosimilars boosting access, adherence, savings
Dedicated focus on women’s health across contraception to menopause, spun off 2021 (OGN), targets ~49.6% of global population with tailored medicines and services.
Biosimilars and established brands deliver cost savings: global biosimilars market >$15B (2024); typical 20–40% price reduction vs originators.
Patient support raises adherence ~10–20%, reducing nonadherence burden (US$100–300B in US); supply in 140+ countries (2024) ensures continuity.
| Metric | 2024 value |
|---|---|
| Global population targeted | 49.6% |
| Biosimilars market | >$15B |
| Country reach | 140+ |
Customer Relationships
Scientific engagement with HCPs
Scientific engagement with HCPs focuses on medical education, detailing, and peer exchange through accredited programs and digital symposia to increase guideline-aligned prescribing. In 2024 WHO and ICH guidance (including E2B standards) underpin adverse event reporting and case discussion workflows. Provide unbiased data, validated tools, and CME credits to support evidence-driven dialogue. Maintain compliant interactions per local regulatory codes and pharmacovigilance requirements.
Value partnerships with payers
Organon prioritizes value partnerships with payers via HEOR evidence and budget-impact models to support >50 payer negotiations in 2024, piloting outcomes contracts tying reimbursement to real-world outcomes. Joint initiatives target adherence and access programs with co-funded patient support and digital reminders; transparent pricing and supply commitments cover ~95% of demand forecasts. Regular quarterly business reviews and secure data sharing drive continuous optimization.
Patient‑centric services
Patient-centric services focus on streamlined onboarding, affordability programs and adherence support shown to cut nonadherence costs (US estimates up to $500 billion/year) by improving persistence; digital reminders and 24/7 nurse helplines leverage high smartphone penetration (Pew: ~85% of US adults own a smartphone) to boost engagement. Multilingual educational materials (10+ languages for global reach) and privacy-respecting data use with closed-loop feedback drive measurable outcomes and trust.
KOL and society collaborations
KOL and society collaborations drive advisory boards and guideline input through dozens of expert panels, support registries and CME programs reaching thousands of clinicians annually, and co‑create evidence‑based care pathways in women’s health to improve uptake and outcomes; these efforts elevate Organon’s credibility and expand reach across clinical and payer communities in 2024.
- dozens of expert panels
- thousands of clinicians reached by CME
- registry partnerships for real‑world evidence
Government and tender relationships
Compliant HCP engagement; outcomes-based payer pilots >50; supply coverage ~95%
Organon sustains compliant HCP scientific engagement, supporting dozens of expert panels and CME reaching thousands of clinicians in 2024, while piloting outcomes-based contracts in >50 payer negotiations. Patient services cover ~95% of demand forecasts with multilingual support (10+ languages) and digital adherence tools; smartphone reach ~85% in key markets. Pharmacovigilance and SLA-driven frameworks ensure on-time delivery and HTA alignment.
| Metric | 2024 | Notes |
|---|---|---|
| Payer negotiations | >50 | includes outcomes pilots |
| Supply coverage | ~95% | aligned to forecasts |
| CME reach | thousands | global programs |
| Languages | 10+ | patient materials |
Channels
Hospital and retail pharmacy distribution
Hospital and retail pharmacy distribution is the primary route for dispensing and patient counseling, with IQVIA estimating about 4.2 billion US prescriptions dispensed annually in 2024, driving point‑of‑care adherence. Integration with wholesalers and 3PL logistics partners ensures national availability and cold‑chain integrity for temperature‑sensitive products, reducing spoilage rates flagged at under 2% in well‑controlled networks. This channel supports therapeutic substitution and formulary execution through contracting, rebates, and pharmacy benefit manager workflows.
Direct sales to providers and institutions
Field teams engage clinics, hospitals and fertility centers, providing samples, education and on-site service support while managing contracts and inventory planning to meet site protocols. Teams tailor solutions to local workflows and regulatory requirements to improve uptake and compliance. Organon, spun off from Merck in 2021, operates in over 140 countries, leveraging this footprint to scale provider relationships.
Tender and procurement platforms
Tender and procurement platforms give Organon access to national and regional buying groups (public procurement ≈12% of global GDP per OECD), forcing competition on value, quality and supply reliability; securing volume via multi‑year awards typically spanning 3–5 years; and meeting strict documentation and audit‑trail requirements for compliance and traceability.
Digital engagement and e‑detail
- Remote detailing — real‑time metrics, higher reach
- Webinars — scalable CME and KOL access
- Portals — 60–75% HCP adoption (2024) for on‑demand content
- Insights capture — behavior data to refine messaging
NGO and public health programs
Partner with NGOs and public-health programs to reach underserved populations where WHO reports 94% of maternal deaths occur in low- and middle-income countries; align donations, tiered pricing and education to address an estimated 257 million women with unmet need for modern contraception (UN/WHO data). Leverage outreach networks and community health workers to improve adherence and support national women’s health initiatives through co-funded programs and capacity building.
- Partner reach: NGOs + CHWs
- Pricing: donations + tiered access
- Adherence: outreach-driven
- Policy: support national initiatives
Global reach 140+ countries — US Rx 4.2B, HCP portals 60–75%
Hospital and retail pharmacy distribution is primary (US prescriptions ~4.2B in 2024) with wholesalers/3PLs preserving cold‑chain (spoilage <2%). Field teams support clinics, hospitals and fertility centers across 140+ countries, managing samples, contracts and inventory. Digital channels (HCP portals adoption 60–75% in 2024) plus tenders (public procurement ≈12% GDP) drive access and formulary execution.
| Metric | Value (2024) |
|---|---|
| US prescriptions dispensed | 4.2B |
| Countries served | 140+ |
| HCP portal adoption | 60–75% |
| Public procurement share | ≈12% GDP |
| Cold‑chain spoilage | <2% |
Customer Segments
Women and patients across life stages
Women and patients across life stages are end users for contraception, fertility and menopause care, with about 1.9 billion women of reproductive age worldwide and an estimated 257 million with unmet need for modern contraception. Nearly 1.2 billion women are projected to be postmenopausal by 2030, showing diverse clinical and geographic needs. Education and affordability support improve uptake and outcomes, which drive word-of-mouth and influence policy priorities.
Healthcare providers and clinics
OB/GYNs, primary care, fertility specialists and hospitals drive therapy choice and adherence—WHO estimates adherence to long-term therapies is ~50% in developed countries—so reliable supply and robust clinical evidence are critical. These clinicians value medical education and service support to influence prescribing for the ~130 million births globally each year and fertility care pathways.
Payers and PBMs
Payers and PBMs rigorously assess cost‑effectiveness and real‑world outcomes to drive formulary placement and utilization management, emphasizing value over brand. They seek predictable pricing and secure supply chains to control spend and avoid disruptions. In 2024 the three largest PBMs together manage roughly 80% of US prescription claims, increasing leverage in pricing and access decisions. They favor biosimilars that demonstrably reduce net cost and total cost of care.
Government and public health systems
Government and public health systems procure medicines and devices via national tenders for programs (HIV, TB, immunization), stressing access, equity and continuous pharmacovigilance; WHO reports 155 countries maintain an essential medicines list, driving tender priorities and stock policies. Compliance, auditability and timely reporting are mandatory for contract award and reimbursement.
- Procurement: tenders for national programs
- Focus: access, equity, essential medicines
- Governance: compliance and auditability
- Safety: pharmacovigilance reporting
Distributors and pharmacy chains
Distributors and pharmacy chains act as intermediaries extending Organon reach and patient services, with pharmacy channels accounting for roughly 60% of retail prescription volumes in major markets (2024 industry data). They optimize inventory, forecasting and replenishment to reduce stockouts and working capital. Their retail presence creates adherence touchpoints and patient-facing programs. They share point-of-sale demand signals that improve planning and SKU assortment.
- Role: intermediaries and service reach
- Operations: inventory, forecasting, replenishment
- Impact: retail adherence touchpoints
- Data: POS/demand signals for planning
1.9B women drive demand; payers force value
Women across life stages (1.9B reproductive-age; 257M unmet contraception; ~1.2B postmenopausal by 2030) and clinicians (OB/GYNs, PCPs; ~50% adherence) drive product choice. Payers/PBMs (top 3 ≈80% US claims) demand cost-effectiveness. Governments (155 countries EML) procure via tenders. Distributors/pharmacies (~60% retail Rx volume) enable access.
| Segment | Key stat (2024) |
|---|---|
| Women | 1.9B; 257M unmet |
| Clinicians | ~50% adherence |
| PBMs/Payers | Top3 ≈80% US claims |
| Pharmacies | ~60% retail Rx |
Cost Structure
R&D and clinical trial expenses
R&D and clinical trial costs cover discovery, IND-enabling work, trials and post‑marketing studies; industry estimates place average cost to develop a new drug at about $2.6B (Tufts 2020) and IQVIA reported 2024 median pivotal Phase III trial costs near $150M, with investigator/site fees, site overheads and data management often accounting for 30–50% of trial budgets; HEOR and real‑world evidence programs and regulatory/ethics submissions add recurring multi‑million dollar spend.
Manufacturing and COGS
APIs, biologics materials and fill-finish dominate Manufacturing and COGS with high raw-material, reagent and single-use consumable spend, driving variable unit costs. Quality control, validation and regulatory compliance add recurring QA/QC labor and testing costs and increase batch cycle time. Depreciation of plant/equipment and CDMO fees represent significant fixed costs; logistics, cold chain and regulated waste management inflate distribution and disposal expenses.
Commercial and market access costs
Organon’s 2024 commercial and market access cost base centers on field forces, medical affairs, and marketing, with major investments in samples, HCP education, and congress participation to support launches and lifecycle management. Pricing analytics and payer negotiation teams drive formulary access and rebate strategies amid tighter 2024 payer budgets. Digital platforms and CRM tools underpin targeted multichannel engagement and rep efficiency. These functions constitute the bulk of commercial SG&A in 2024.
Regulatory, PV, and compliance
Regulatory, PV, and compliance costs cover licensing, submissions, and inspections (including FDA/EMA user fees and third-party dossier preparation); safety monitoring and risk management plans with ongoing pharmacovigilance; legal, audit, and mandatory training; and data privacy and cybersecurity programs. In 2024 FDA prescription drug user fees were approximately 2.7 billion USD, reflecting rising regulatory spend.
- Licensing & submissions: dossier, user fees, inspections
- PV & RMP: signal detection, AE reporting
- Legal/audit/training: compliance certifications
- Data privacy/cyber: HIPAA/GDPR controls, breach response
Corporate and overhead
Corporate and overhead for Organon cover management, IT, and shared services driving SG&A; 2024 guidance targeted company net sales of about $5.6 billion, with SG&A absorbing a high single-digit to low double-digit percent of revenue as investments in digital and back-office modernization continued. Facilities, utilities, insurance and partnership/licensing fees add fixed and variable layers; FX, taxes and financing costs influence net margins and cash flow.
R&D, trials and regulatory fees squeeze drugmakers' margins
R&D/clinical trials drive high fixed and variable costs (Tufts 2020 drug development ~$2.6B; IQVIA 2024 median Phase III ~$150M). Manufacturing/COGS reflect expensive APIs, biologics, QA/QC and CDMO fees; logistics/cold chain add variable costs. 2024 regulatory/user fees (~$2.7B FDA) plus SG&A (Organon 2024 net sales ~$5.6B; SG&A high single- to low double-digit % of revenue) pressure margins.
| Item | 2024/Ref |
|---|---|
| Drug dev cost | $2.6B (Tufts 2020) |
| Phase III median | $150M (IQVIA 2024) |
| FDA user fees | $2.7B (2024) |
| Organon net sales | $5.6B (2024) |
Revenue Streams
Women’s health product sales
Organon's women's health product sales span contraceptives, fertility treatments and menopause therapies, addressing both retail and institutional channels; global women of reproductive age numbered about 1.9 billion in 2024 (UN), underpinning broad demand. Programs for patient education and adherence support uptake and persistence. Revenue mix is geographically diversified across North America, Europe and emerging markets.
Biosimilars portfolio revenues
Sales from approved biosimilar antibodies and biologics generate recurring revenue for Organon, largely secured through payer access and public tenders. Price‑volume trade‑offs expand market reach, particularly in tender-driven markets where lower prices drive higher volumes. Ongoing favorable price‑volume dynamics underpin revenue visibility and support reinvestment in portfolio expansion.
Established brands sales
Organon's established brands deliver steady revenue from legacy medicines with predictable, diagnosis-driven demand; these portfolios underpin cash flow stability. The products benefit from a broad geographic presence in over 140 countries, supporting market penetration and pricing resilience. Consistent supply reliability helps maintain market share in mature segments. Incremental growth is achieved through lifecycle tweaks such as line extensions and dosing/formulation improvements.
Licensing and co‑development income
Licensing and co‑development income combines milestone payments, ongoing royalties and option fees to monetize assets while sharing development risk; Organon used in‑ and out‑licensing to optimize portfolio fit and access novel technologies, supporting commercial flexibility. In 2024 Organon reported $3.4 billion in net sales, underpinning licensing leverage.
- Milestones, royalties, option fees
- In-/out‑licensing for portfolio fit
- Risk‑sharing on dev costs
- Access to novel tech
Public tenders and contracting
Public tenders and contracting leverage multi‑year framework agreements with governments to secure volumes; in 2024 global public pharmaceutical procurement was estimated at about $360B, underpinning predictable demand. Volume‑based pricing across indications supports lower unit prices and steady margins while enabling capacity planning. These contracts demand strict service and quality levels and KPIs tied to payments.
- Multi‑year frameworks: predictable revenues
- Volume pricing: lower unit cost, higher throughput
- 2024 public procurement ~ $360B
- Requires strict SLA/KPI compliance
Global women's-health: $3.4B sales; procurement $360B
Organon derives revenue from women's‑health therapies, biosimilars, legacy brands and licensing, with $3.4B net sales in 2024 and presence in 140+ countries. Public tenders and multi‑year government contracts (global procurement ≈ $360B in 2024) provide predictable volume revenue. Patient programs and lifecycle management sustain uptake and margin resilience.
| Metric | 2024 |
|---|---|
| Net sales | $3.4B |
| Women of reproductive age | 1.9B (UN) |
| Public procurement | $360B |
| Countries | 140+ |